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Abstract
Background: Despite its high prevalence, migraine remains underdiagnosed and undertreated. ID-Migraine is a
short, self-administrated questionnaire, originally developed in English by Lipton et al. and later validated in several
languages. Our goal was to validate the Hungarian version of the ID-Migraine Questionnaire.
Methods: Patients visiting two headache specialty services were enrolled. Diagnoses were made by headache specialists
according to the ICHD-3beta diagnostic criteria. There were 309 clinically diagnosed migraineurs among the 380 patients.
Among the 309 migraineurs, 190 patients had only migraine, and 119 patients had other headache beside migraine,
namely: 111 patients had tension type headache, 3 patients had cluster headache, 4 patients had medication overuse
headache and one patient had headache associated with sexual activity also. Among the 380 patients, 257 had only a
single type headache whereas 123 patients had multiple types of headache. Test-retest reliability of the ID-Migraine
Questionnaire was studied in 40 patients.
Results: The validity features of the Hungarian version of the ID-Migraine questionnaire were the following: sensitivity
0.95 (95% CI, 0.92–0.97), specificity 0.42 (95% CI, 0.31–0.55), positive predictive value 0.88 (95% CI, 0.84–0.91), negative
predictive value 0.65 (95% CI, 0.5–0.78), missclassification error 0.15 (95% CI, 0.12–0.19). The kappa coefficient of the
questionnaire was 0.77.
Conclusion: The Hungarian version of the ID-Migraine Questionnaire had adequate sensitivity, positive predictive value
and misclassification error, but a low specificity and somewhat low negative predictive value.
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Background
Migraine is a common disease, which affects 14% of the
population, and 18% of women [1] globally. In the USA,
its lifetime prevalence is 25% in women [2]. It affects
mainly the active, working, young adult population [3].
In Hungary, only one population based headache epi-
demiology study has been made to date [4]. This study
reported 67% lifetime prevalence for any kind of head-
ache: the one-year prevalence of migraine without aura
was 7.6%, and the one-year prevalence of migraine with
aura was 2%. Only 43% of migraineurs had ever con-
sulted any physician because of their headache, and 15%
of patients missed school or work because of their head-
ache in the previous year.
According to the report of Global Burden of Disease
studies, migraine is the third cause of disability in 15–
49 years old men and women [5]. The disability, caused
by migraine, affects many aspects of life, and leads to
both physcial and emotional impairment [6]. In one
Swedish study, researchers found that in migrainous pa-
tients, the health-releated quality of life is significantly
worse, not only during the migraine attacks, but also be-
tween attacks, compared to healthy controls. In another
study, 65% of migraine patients reported some degree of
absenteeism from their workplace or school due to their
headache [6]. The indirect costs of migraine are consid-
erable: in the USA alone, approximately 13 billion dol-
lars are spent each year for migrainre-related
absenteeism from workplace and reduced ability to work
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[7]. Despite migraine’s serious negative effects on the
individual, less than half of the patients ever recieve a
medical diagnosis of headache [8, 9]. Furthermore, mi-
graine is suboptimally treated, with only one-third re-
ceiving some kind of migraine-specific medication [10].
There are several factors of migraine being underdiag-
nosed and undertreated. The most important factor is
that many migraine patients – even those with quite
strong headaches – do not consult their doctors because
of their headache, and therefore do not receive the diag-
nosis of migraine [8]. In the UK, 4.4% of the population
would see a general practitioner because of a headache
problem in a given year, 34% of whom (ie. 1.5% of the
population) would be prescribed a migraine medication
(acute or prophylactic), while only 2.1% of those who
consult would be referred to a neurologist [11]. This
compares to a 14.3% one-year prevalence of migraine in
the UK [12]: the reason for the low consultation rates is
not self-evident [11]. The severity of the attack may not
be a decisive factor in consulting: an American survey
found that 61% of those who had never consulted
reported severe or very severe pain and 67% reported
severe disability or the need for bed rest during their
migraines [13]. A further difficulty in diagnosing
migraine may be the duration of the doctor-patient
meeting, which may not be enough to discuss the char-
acteristics of the headaches. Furthermore, a number of
primary care physicians may not have an adequate
knowledge about headaches [14], and the IHS criteria
are excessively complex and time-consuming for routine
application in primary care [15, 16].
In order to facilitate the detection of migraine in pri-
mary care, Lipton et al. (2003) developed a brief, self-
administered questionnaire, the ID-Migraine [17]. The
questionnaire contains two pre-screening questions, one
asking about headache-related disability, the other asking
whether the patient would like to consult a doctor because
of the headache. This is followed by three screening
questions pertaining to the previous three months. These
screening questions ask about headache-related disability,
nausea and sensitivity of light. The ID-Migraine indicates
migraine if a patient answered “yes” at least to two of the
three screening questions. In the original study, the sensi-
tivity of the ID-Migraine Questionnaire was 0.81, the
specificity was 0.75, and the positive predictive value was
0.93. Test-retest reliability was good, with a kappa of 0.68.
The ID-Migraine Questionnaire was therefore found to be
a valid, reliable, and easy-to-use screening instrument to
detect migraine, for patients presenting in primary care.
The authors emphasized that the ID-Migraine Question-
naire is not a diagnostic instrument by itself, so a thor-
ough evaluation of patients is necessary to make the
diagnosis of migraine. Subsequently, the questionnaire
was validated in Italian [18], Portuguese [19] and Turkish
[20] languages with adequate results (Table 1). The ques-
tionnaire has been used in many specialty fields to screen
migraine, not only in primary care [16, 21], but also in
headache centers and neurology clinics [18, 19, 22]. More-
over, the questionnaire was successfully used for screening
migraine patients in the emergency department [23], in a
temporomandubular and orofacial pain clinic [24], and
also in opthalamic and ear, nose and throat clinics [25].
The ID-Migraine Questionnaire proved to be reliable not
only in adults, but also among adolescents [26]. It was also
used in large-scale studies of migraine epidemiology [21]
and genetic studies [27].
In this study we present the validity features of the
Hungarian version of the ID-Migraine Questionnaire.
Methods
Patients between 18 and 65 years of age, presenting at
the Headache Service of the Department of Neurology,
Semmelweis University or the Headache Service of
Esztergom Hospital, and reporting two or more head-
aches in the previous 3 months were involved. Both
Services worked with the same methology. In order to
include at least 300 patients in the study (ie. 100 patients
per questionnaire item, which is a widely accepted and
conservative way of assuring an adequate sample size in
validation studies [28] we involved all patients visiting
these Services in a two-year period who were willing to
participate and gave informed consent to processing
their results. The study protocol had been approved by
the ethics committee of Semmelweis University. Patients
completed the questionnaire at the occasion of their
medical visit. Most of the patients filled in the question-
naire before the medical visit, ie. while they were waiting
to be seen by the neurologist, who, on the other hand,
Table 1 Validation results of the ID-Migraine questionnaire in different languages
Location of the research Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
English,2003[17] primary care 0.81 (0.77 to 0.85) 0.75 (0.64 to 0.84) 0.93 (0.90 to 0.96) NI
Italian, 2007[18] headache centers 0.95 (0.91 to 0.98) 0.72 (0.62 to 0.82) 0.88 (0.82 to 0.93) 0.87 (0.78 to 0.95)
Turkish, 2007[19] neurology outpatient clinics 0.92 (NI) 0.63 (NI) 0.72 (NI) 0.88 (NI)
Portuguese, 2008[20] headache outpatient clinics 0.94 (0.87 to 0.97) 0.60 (0.46 to 0.73) 0.80 (0.71 to 0.87) 0.85 (0.70 to 0.94)
NI=no information, PPV = positive predictive value, NPV = negative predictive value, CI confidence interval
Note: NPV was not reported in the English study, classification errors were not reported in any of the studies, and no confidence intervals were reported in the
Turkish study
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did not use the questionnaire to ascertain the diagnosis
that was based on the interview with the patient. A
minority of the patients filled in the questionnaire while
they were waiting for their written documentation, ie.
after the medical visit. The patients also completed a
9-item Hungarian migraine screener (the MDX ques-
tionnaire), developed and validated by our group [29],
which was used to collect information about the clinical
characteristics of their headaches in more detail, but was
not included as a reference tool in the validation process
of ID-Migraine. All the patients underwent detailed
internal medicine and neurological examination. The
gold standard was the neurologists’ clinical diagnosis, ac-
cording to the International Classification of Headache
Disorders (ICHD3-β). As in the original English version
[17], the Hungarian version of the ID-Migraine was con-
sidered positive for migraine if a patient answered “yes”
at least to two of the three screening questions. The re-
sponses to the ID-Migraine Questionnaire were then
compared with the clinical diagnosis of migraine: if a pa-
tient had a diagnosis of migraine, she/he was considered
a migraineur regardless of having other headaches beside
migraine or not. Based on the primary diagnosis, the
questionnaire’s sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV), and classi-
fication error were calculated. These parameters were
calculated for the individual items of the ID-Migraine
Questionnaire, as well. Based on previously reported val-
idation studies [18, 19] we also calculated these values in
subgroups of patients according to sex, age (equal or
below 44 years and above 44 years) and disease duration
(equal or below 12 years and above 12 years) in order to
have a more thorough vision of the Hungarian version’s
performance.
In addition, to evaluate the characteristics of the
Hungarian ID-Migraine Questionnaire the receiver oper-
ating curve (ROC) was constructed among the 380
patients with different sensitivity (true positive rate) and
100-specificity (false positive rate) values according to the
minimum number of positive answers to the ID-Migraine
Questionnaire (0, 1, 2, and 3 positive answers).
Among the 380 headache sufferers, 40 patients com-
pleted the ID-Migraine Questionnaire twice, the second
time was also during a follow-up visit. Test-retest reli-
ability, using the Cohen’s Kappa, was calculated in these
40 patients. The following values of Cohen’s Kappa were
used to evaluate the level of agreement [30]: < 0: no
agreement; 0.0–0.20: slight agreement; 0.21–0.40: fair
agreement; 0.41–0.60: moderate agreement; 0.61–0.80:
substantial agreement; 0.81–1.0: perfect agreement.
We used an Excel spreadsheet for data input, and an
online statistical package (VassarStats, http://vassarstats.-
net/) to calculate the ID-Migraine’s validity features
(sensitivity, specificity, PPV, NPV), the confidence inter-
vals thereof, misclassification error and test-retest
reliability.
Results
A total of 380 patients completed the Hungarian version
of the ID-Migraine Questionnaire. Among the 380
patients, 80% were female and 20% were male. The me-
dian age was 36 years, the interquartile range was
19.8 years. The median disease duration was 10 years,
the interquartile range was 16 years.
Table 2 summarizes the clinical headache diagnoses
among the 380 patients. The number of clinically diag-
nosed migraineurs was 309; among them, 190 had only
migraine, whereas 119 patients had another headache
diagnoses beside migraine. The total number of
non-migraine patients was 71; the primary diagnosis was
tension type headache (TTH) in 45 patients, cluster
headache in 19 patients, and other headache in 7 pa-
tients. Among the 380 patients, 257 had only one type
headache, namely: 190 patients had only migraine, 44
Table 2 Clinical headache diagnoses among the 380 patients who completed the ID-Migraine questionnaire
Primary diagnosis Number Secondary diagnosis Number
Migraine 309 (251 episodic and 58 chronic) none 190
tension type headache 111
cluster headache 3
medication overuse headache 4
headache associated with sexual activity 1
Tension type headache 45 (12 episodic and 33 chronic) none 44
headache associated with sexual activity 1
Cluster headache 19 (18 episodic and 1 chronic) none 16
tension type headache 2
SUNCT syndrome 1
Other headache 7 none 7
MOH medication overuse headache, SUNCT short-lasting unilateral neuralgiform headache with conjunctival injection and tearing
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had only TTH, 16 had only cluster headache and 7 had
only other type of headache. The other 123 patients had
more than one type of headache at the time of the study.
Among the 380 patients, 334 had a positive ID-Migraine
score; 293 of them had a clinical diagnosis of migraine.
Among the 45 patients, clinically diagnosed with TTH, 23
had a positive ID-Migraine score, as did 16 of the 19
patients, whose clinical diagnosis was cluster headache.
Table 3 contains the number of positive ID-Migraine
Questionnaires in the clinical headache groups.
Figure 1 shows the ROC curve with different cut off
points (0, 1, 2, or 3 “yes” answere) to demonstrate the
characteristics of the Hungarian ID-Migraine Ques-
tionnaire. To calculate validity measures we used the
original cutoff value of at least two “yes” answers out
of the three screening questions as reported by Lipton
et al. [17].
Based on the whole sample (n = 380), the quality scores
of the Hungarian version of the ID-Migraine Question-
naire were the following: sensitivity 0.95 (95%CI, 0.92–
0.97), specificity 0.42 (95%CI, 0.31–0.55), positive predict-
ive value (PPV) 0.88 (95%CI, 0.84–0.91), negative predict-
ive value (NPV) 0.65 (95%CI, 0.5–0.78), misclassification
error 0.15 (95%CI, 0.12–0.19).
Fourty of the 380 patients also completed the ques-
tionnaire during a follow-up visit. In this sample, the
clinical diagnoses were as follows: 31 patients had mi-
graine, 6 had TTH, 2 had cluster headache, and one had
other (cervicogenic) headache. Two of the patients’ clin-
ical migraine diagnoses changed between the first and
second ID-Migraine Questionnaire assessments: one had
migraine as the initial diagnosis and TTH at follow-up,
the other had TTH as the initial diagnosis and migraine
at follow-up. The median interval between filling out the
ID-Migraine Questionnaire for the first and second time
was 90.5 days, the interquartile range was 475 days. At
the time of the first completion, 36 of the 40 patients
had a positive ID-Migaine Questionnaire. At the second
time, 34 of the 40 patients had a positive test. The kappa
coefficient of the questionnaire was 0.77, indicating a
substantial agreement between the assesments. The
overall percent of agreement was 0.95, the percent of
positive agreement was 0.94.
Table 4 summarizes the quality scores for the separate
items of the ID-Migraine Questionnaire using the data
Table 3 The number of ID-Migraine Questionnaire positive
patients in clinically diagnosed headache groups
Clinically diagnosed patients ID-Migraine Questionnaire
positive patients
total sample size: n = 380 n = 334
migraine group: n = 309 n = 293
tension type group: n = 45 n = 23
cluster type group: n = 19 n = 16
other headache group: n = 7 n = 2
Fig. 1 The receiver operating curve of the ID-Migraine Questionnaire in the study population. The curve shows the sensitivity and specificity
values according to the minimum number of positive answers for the ID-Migraine Questionnaire. Thresholds were determined according to the
minimum number of positive answers to the ID-Migraine Questionnaire (0,1, 2 and 3 positive answers). 0: sensitivity: 1.00 (95% CI; 0.98–1.00);
specificity: 0.00 (95% CI; 0.00–0.06). 1: sensitivity: 0.997 (95% CI; 0.98–1.00); specificity: 0.11 (95% CI; 0.05–0.22). 2: sensitivity: 0.95 (95% CI; 0.92–0.97);
specificity: 0.42 (95% CI; 0.31–0.55). 3: sensitivity: 0.71 (95% CI; 0.65–0.76); specificity: 0.79 (95% CI; 0.67–0.87)
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of 380 patients. All of the items (nausea, photophobia and
disability) had high sensitivity and positive predictive value
(> 0.8). We found the highest sensitivity for the disability
(0.97), similarly to the Italian ID-Migraine Questionnaire.
Nausea showed the highest positive predictive value (0.9).
By contrast, we found signifcantly lower scores for the
negative predictive value and specificity compared to sen-
sitivity and positive predictive value.
Table 5 presents the quality scores of the questionnaire
in the clinically relevant subgroups, namely according to
sex, age (equal or below 44 years and above 44 years)
and disease duration (equal or below 12 years and above
12 years). While the sensitivity and specificity of the
ID-Migraine was the same in female and male patients,
the PPV was noticeably higher, whereas the NPV and
misclassification error were noticeably lower in females
than males. There were no other substantial differences
between the subgroups.
Given that the Hungarian version of the ID-Migraine
had substantially lower specificity and NPV than the ori-
ginal and previous translations, we scrutinized those
patients whose were diagnosed with nonmigraine head-
aches, especially whose ID-Migraine scores were positive,
as was the case of 51% of TTH patients, 84% of cluster
headache patients, and 29% of other headache patients,
making use of the MDX questionnaire that contained the
clinical characteristics of their headaches in more detail.
Table 6 shows the clinical characteristics of these patients’
headaches. All patients in all diagnostic groups reported
an at least moderate severity of headache, regardless of
their ID-Migraine score. In the TTH group, patients with
a positive ID-Migraine score had an average of 3.3
migrainous features, compared to 2.0 in their ID-Migraine
negative peers. In the cluster headache group, patients
with a positive ID-Migraine score had, on average, 4.0
migrainous features, compared to 0.3 in ID-Migraine
negative patients. In the group of other non-migraine
headaches, patients with a positive ID-Migraine score had
an average of 3.5 migrainous features, whereas the
ID-Migraine negative patients had 2.0.
In the TTH group, 23 patients (4 episodic and 19
chronic) had a positive ID-Migraine score. Based on the
clinical characteristics available from the MDX question-
naires, 14 patients (1 episodic and 13 chronic) could be
considered as having migraines as well, whereas 3
episodic and 6 chronic TTH patients did not meet the
criteria of migraine. The difference between the distribu-
tion of suspected migraine and no migraine was not sig-
nificant (Chi square test: p = 0.106).
In the cluster headache group, 16 patients (15 episodic
and 1 chronic) had a positive ID-Migraine score. As all
of these patients were followed up at the Dept. of Neur-
ology, and their clinical documentation was available, we
performed a retrospective chart review to ascertain the
diagnosis. Based on the clinical characteristics (strictly
unilateral attacks; presence of ipsilateral autonomic fea-
tures; periodicity) the diagnosis of cluster headace was
confirmed in all of them. However, as 84% of cluster
Table 4 Quality scores separately for the items of the Hungarian version of the ID-Migraine Questionnaire (n = 380)
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) Classification error (95% CI)
Nausea 0.86 (0.82–0.90) 0.59 (0.47–0.70) 0.9 (0.86–0.93) 0.49 (0.38–0.60) 0.19 (0.15–0.23)
Photophobia 0.83 (0.78–0.86) 0.58 (0.45–0.69) 0.89 (0.85–0.93) 0.43 (0.33–0.54) 0.22 (0.18–0.27)
Disability 0.97 (0.94–0.98) 0.15 (0.08–0.26) 0.83 (0.79–0.87) 0.52 (0.3–0.74) 0.18 (0.15–0.23)
ID-migraine positive
(≥2 “yes”)
0.95 (0.92–0.97) 0.42 (0.31–0.55) 0.88 (0.84–0.91) 0.65 (0.5–0.78) 0.15 (0.12–0.19)
PPV = positive predictive value, NPV = negative predictive value, CI confidence interval
Table 5 Quality scores of the Hungarian version of the ID-Migraine questionnaire in the clinically relevant subgroups
N (%) Sensitivity(95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) Classification error (95% CI)
Sex
Women 304 (80%) 0.95 (0.92–0.97) 0.47 (0.30–0.65) 0.93 (0.90–0.96) 0.55 (0.36–0.73) 0.1 (0.07–0.14)
Men 76 (20%) 0.95 (0.81–0.99) 0.39 (0.24–0.56) 0.63 (0.49–0.75) 0.88 (0.60–0.98) 0.32 (0.22–0.44)
Age
≤ 44 years 262 (69%) 0.96 (0.92–0.98) 0.44 (0.29–0.60) 0.89 (0.84–0.93) 0.69 (0.48–0.85) 0.13 (0.09–0.18)
> 44 years 118 (31%) 0.94 (0.86–0.98) 0.48 (0.27–0.69) 0.87 (0.78–0.93) 0.69 (0.41–0.88) 0.16 (0.10–0.24)
Duration of illness
≤ 12 years 228 (60%) 0.96 (0.89–0.99) 0.41 (0.25–0.59) 0.82 (0.74–0.89) 0.78 (0.52–0.93) 0.18 (0.12–0.26)
> 12 years 152 (40%) 0.94 (0.85–0.98) 0.33 (0.09–0.69) 0.93 (0.84–0.97) 0.38 (0.10–0.74) 0.13 (0.06–0.21)
PPV = positive predictive value, NPV = negative predictive value, CI confidence interval
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headache patients had a positive ID-Migraine score and
they were overrepresented in the sample, we also calcu-
lated the quality scores excluding these patients. In this
calculation, sensitivity was 0.95 (95%CI: 0.92–0.97), spe-
cificity was 0.52 (95% CI: 0.38–0.66), PPV was 0.92 (95%
CI: 0.88–0.95), NPV was 0.63 (95% CI: 0.47–0.77) and
misclassification error was 0.11 (95%CI: 0.08–0.15).
Finally the two patients who had other non-migrainous
headaches and a positive ID-Migraine score could be con-
sidered as having migraines as well, based on the charac-
teristics of their headaches.
Discussion
Our results demonstrated that the Hungarian version
of the ID-Migraine Questionnaire is a reliable screen-
ing instrument for migraine based on data collected
at specialist headache centres. The fact that all pa-
tients fully completed the questionnaire indicates that
it is easy to understand and use, so it could be used
as a screening tool in primary care, and also for re-
search purposes. The sensitivity and positive predict-
ive value of the Hungarian version of the ID-Migraine
Questionnaire were quite similar to those of the ori-
ginal English version [17], with the Hungarian version
having a higher sensitivity (0.95 vs. 0.81). The classifi-
cation error (which had not been reported in the pre-
vious validation studies) was also acceptable. On the
other hand, the specificity of the Hungarian version
was markedly lower, and the negative predictive value
was also somewhat lower than in the previous valid-
ation studies. It is important to note, that our sample
was quite similar to other validation studies where
the participants had also been recruited from head-
ache centers [18–20, 29, 31–34].
All of the items (nausea, photophobia and disability)
had high sensitivity and positive predictive value (> 0.8).
This is in agreement with the Italian and Portugese ver-
sions of ID-Migraine Questionnaire [18, 19]. We found
the highest sensitivity for the disability (0.97), similarly
to the Italian ID-Migraine Questionnaire [18]. The nau-
sea showed the highest positive predictive value (0.9),
similarly to the portugese version of ID-Migraine Ques-
tionnaire [19], which supports the previous studies that
headache-related nausea is an important accompaining
symptom and has high impact on migraine [8, 35–39].
From the 309 clinically diagnosed migraine patients, 293
had positive ID-Migraine scores. This result supports the
previous findings, that ID-Migraine Questionnaire has a
high screening accuracy [17–19, 22, 25, 40–42].
In addition, the quality scores of the questionnaire
showed no significant difference between clinically rele-
vant subgroups, divided by sex, age and disease duration,
similarly to the Portuguese and Italian versions of
ID-Migraine Questionnaire [18, 19]. This suggests that
the questionnaire may be used in the general population.
The cause of the lower specificity and NPV of the
Hungarian version (0.42 vs 0.75 for the English version)
may in part be due to the high number of false positive
patients among the clinically diagnosed cluster headache
and TTH patients. In particular, cluster headache was
overrepresented in the sample (the prevalence of cluster
headache patients in the sample was 5.0% versus a
roughly 0.1% prevalence in the general population [43].
Sixteen of these 19 patients had a positive ID-Migraine
score, which is not surprising considering the high inci-
dence of nausea and photophobia occurring during clus-
ter headache attacks, described first by Bahra et al. [44],
and also corroborated by a Hungarian study [45] where
the prevalence of nausea and photophobia during a clus-
ter headache attacks were 43% and 68%, respectively. As
shown in the Results section, eliminating the cluster
headache patients resulted in a significant rise in the
specificity, from 42% to 52%, while, interestingly, the
NPV did not change much. Given the fact that the spon-
taneous occurrence of cluster headache in a similar sam-
ple from the general population would not be expected
to be more than 1 patient, it may be safe to suggest that
the specificity of the Hungarian version may be notice-
ably higher in representative samples.
Another issue affecting the specificity and NPV of the
patients may have been a diagnostic error in chronic
TTH patients. As outlined in the Results, 13 of the 19
chronic TTH patients with a positive ID-Migraine score
could be considered migraineurs based on the character-
istics of their headaches. As follow up data were not
available for most TTH patients, this suggestion could
Table 6 The self-reported headache characteristics of the non-migraine patients versus their ID-Migraine status
Clinical diagnosis ID-Migraine Number of patients Worse with movement Nausea Vomiting Photophobia Phonophobia
Tension type headache positive 23 14 17 1 12 9
negative 22 12 1 0 2 8
Cluster headache positive 16 9 9 8 12 10
negative 3 0 0 0 0 1
Other headache positive 2 1 1 0 1 2
negative 5 2 0 0 0 3
Note: All patients reported an at least moderate severity of pain so this was not included In Table 6
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neither be proved or disproved: however it is plausible
that patients having chronic TTH and episodic mi-
graines may not have had the latter diagnosis during
their clinical visit. Our clinical experience with patients
(not taking part in this study) who are followed up with
a headache diary is that at least 20% of the patients who
describe only migraine during the first visit would even-
tually be fund to have tension type headaches (TTH) as
well, and a smaller percentage of patients originally diag-
nosed as ‘pure’ chronic TTH would also have attacks
that fulfil the criteria of migraine. (This experience is
not adequately reflected in the study as the number of
patients included in the test-retest reliability part is still
quite small.) These observations primarily affect the
positive and negative predictive value and may increase
the false positive test ratio, thus reducing the specificity
of the questionnaire, and increasing its sensitivity and
classification error.
A major limitation of our study is that our patients
were recruited from patients visiting specialist headache
services, so the sample is not representative of the gen-
eral population. In particular, patients with episodic
TTH were hugely underrepresented, and cluster head-
ache patients were overrepresented. It is to be expected
that, regardless of the diagnosis, patients with more se-
vere head pain and accompanying symptoms would be
overrepresented, and this may result in better quality
indicators.
A further major limitation, that concerns the applic-
ability of the ID-Migraine in the Hungarian popula-
tion, is represented by the low specificity and low
negative predictive value observed in our sample, the
reasons of which are discussed above. The fact that
test-retest reliability could only be tested in 10.5% of
the patients represents a further limitation, although
this percentage is actually slightly higher, than in the
Portuguese validation study [19]. Finally, the fact
that a minority of patients filled in the questionnaire
after the medical visit is also a limitation, because
the questions asked by the neurologist may have
reinforced the patients’ memories of the characteris-
tics of headache that are the items in the ID-
Migraine questionnaire.
Conclusion
Our validation study proved that the Hungarian version
of the ID-Migraine Questionnaire is a reliable tool to
screen migraine patients in Hungary, with a high sensi-
tivity and positive predictive value. However, mainly be-
cause of the low specificity observed in the current
study, using ID-Migraine as a standalone diagnostic tool
in Hungarian patients is currently not feasible. Further
testing of the instrument is required, preferably in a
sample from the general population.
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